Simoa nf light v2 advantage kit

To collect CSF samples from the monkeys, a lumbar puncture was performed with a 22 G traumatic needle between L4 and L5. The CSF samples were transferred to sterile low-binding microcentrifuge tubes and then centrifuged at 10,000 g at 4 °C for 5 min. Next, the total tau, phospho-tau 181, phospho-tau 231, Aβ42, Aβ40, and NfL peptide levels were analysed for all samples using Quanterix’ ultrasensitivity digital biomarker detection technology with the Simoa® HD-X Analyser™ (Quanterix, Billerica, MA, USA), the latest model of the fully automated Simoa bead-based immunoassay platform. The assay kits used in this study were the Simoa® Neurology 3-Plex A Kit (101,995, Quanterix, USA), the Simoa™ pTau-181 V2 Advantage Kit (103,714, Quanterix, USA), the Simoa™ pTau-231 Advantage Kit (102,292, Quanterix, USA), and the Simoa™ NF-light V2 Advantage kit (104,073, Quanterix, USA).

Quantitative analysis of NfL in plasma samples of patients was performed by single molecule array (SiMoA) technology on the SR-X analyzer from Quanterix (Billerica, MA, United States). NfL levels were determined using the commercially available Simoa NFLIGHT v2 Advantage kit (Item 104,073, Quanterix), according to the manufacturer’s instructions. Briefly, samples, calibrators and two quality controls of known concentrations (high-concentration and low-concentration quality control) were run in duplicate. Samples were run with a 4-fold dilution and results were compensated for this dilution. The mean value of the two NfL measurements (pg/ml) was used for statistical analysis. The limit of quantification was 2.56 pg/mL, and the limit of detection was 0.141 pg/mL. A single batch of reagents was used for all samples; and the intra-assay coefficient of variation was below 14%.